nct_id: NCT05609968
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2022-11-08'
study_start_date: '2023-02-06'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Biological: Sacituzumab Govitecan'
  - drug_name: 'Biological: Pembrolizumab'
long_title: An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled
  Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan
  Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS
  Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)
last_updated: '2025-11-12'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: NA
principal_investigator_institution: Merck Sharp & Dohme LLC
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 614
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- 'The main inclusion criteria include but are not limited to the following:'
- '* Has a histologically or cytologically confirmed diagnosis of metastatic non-small
  cell lung cancer (NSCLC)'
- '* Has confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma
  kinase 1 (ALK-1), or ROS proto-oncogene 1 (ROS-1)-directed therapy is not indicated
  as primary therapy'
- "* Has provided tumor tissue that demonstrates PD-L1 tumor proportion score (TPS)\
  \ \u226550% of tumor cells as assessed by immunohistochemistry (IHC) at a central\
  \ laboratory"
- '* Has a life expectancy of at least 3 months'
- 'Exclude - Exclusion Criteria:'
- 'Exclude - The main exclusion criteria include but are not limited to the following:'
- Exclude - * Has history of a second malignancy, unless potentially curative treatment
  has been completed with no evidence of malignancy for 3 years
- Exclude - * Has received prior systemic chemotherapy or other targeted or biological
  antineoplastic therapy for their metastatic NSCLC
- Exclude - * Has previously received treatment with Topoisomerase 1 inhibitors or
  Trop-2 targeted therapy
- Exclude - * Has received prior therapy with an anti-programmed cell death 1 protein
  (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti anti- programmed
  cell death ligand 2 (PD-L2) agent or with an agent directed to another stimulatory
  or coinhibitory T-cell receptor
- Exclude - * Has received prior radiotherapy within 2 weeks of start of study intervention
  or has radiation-related toxicities requiring corticosteroids
- Exclude - * Has received radiation therapy to the lung that is \>30 Gray (Gy) within
  6 months of the first dose of study intervention
- Exclude - * Has received a live or live-attenuated vaccine within 30 days before
  the first dose of study intervention
- Exclude - * Has received an investigational agent or has used an investigational
  device within 4 weeks before study intervention administration
- Exclude - * Has cardiac disease
- Exclude - * Myocardial infarction or unstable angina pectoris within 6 months of
  enrollment
- Exclude - * History of serious ventricular arrhythmia, high-grade atrioventricular
  block, or other cardiac arrhythmias requiring antiarrhythmic medications; history
  of QT interval prolongation
- Exclude - * New York Heart Association (NYHA) Class III or greater congestive heart
  failure or left ventricular ejection fraction of \<40%
- Exclude - * Has active chronic inflammatory bowel disease
- Exclude - * Has diagnosis of immunodeficiency or is receiving chronic systemic steroid
  therapy or any other form of immunosuppressive therapy within 7 days prior the first
  dose of study medication
- Exclude - * Has known active central nervous system (CNS) metastases and/or carcinomatous
  meningitis
- "Exclude - * Has severe hypersensitivity (\u2265Grade 3) to pembrolizumab or sacituzumab\
  \ govitecan and/or any of their excipients"
- Exclude - * Has active autoimmune disease that has required systemic treatment in
  past 2 years except replacement therapy
- Exclude - * History of (noninfectious) pneumonitis/interstitial lung disease that
  required steroids or has current pneumonitis/interstitial lung disease
- Exclude - * Has active infection requiring systemic therapy
- Exclude - * Has history of human immunodeficiency virus (HIV) infection
- Exclude - * History of hepatitis B or known active hepatitis C virus infection
- Exclude - * Has history or current evidence of any condition, therapy, laboratory
  abnormality, or other circumstance that might confound the results of the study
  or interfere with the participant's participation for the full duration of the study,
  such that it is not in the best interest of the participant to participate, in the
  opinion of the treating investigator
- Exclude - * Have not adequately recovered from major surgery or have ongoing surgical
  complications
short_title: "Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan\
  \ in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell\
  \ Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion\
  \ Score (TPS) \u226550% (MK-3475-D46)"
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Merck Sharp & Dohme LLC
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: "The purpose of this study is to compare pembrolizumab (MK-3475) in combination\
  \ with sacituzumab govitecan with pembrolizumab alone with respect to progression-free\
  \ survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid\
  \ Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review\
  \ (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed\
  \ cell death ligand 1 (PD-L1) tumor proportion score (TPS) \u226550%)."
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Pembrolizumab + Sacituzumab Govitecan
      arm_internal_id: 0
      arm_description: Participants receive sacituzumab govitecan 10mg/kg intravenous
        (IV) infusion once weekly on Day 1 and Day 8 of a continuous 21-day cycle
        until progressive disease (PD) requiring discontinuation, unacceptable toxicity,
        withdrawal of consent, or death. Participants receive pembrolizumab 200mg
        IV infusion on Day 1 every 3 weeks (Q3W) for up to 35 cycles (each cycle length
        = 21 days).
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Biological: Sacituzumab Govitecan'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Biological: Pembrolizumab'
        level_internal_id: 1
        level_suspended: N
    - arm_code: Pembrolizumab
      arm_internal_id: 1
      arm_description: Participants receive pembrolizumab 200mg IV infusion on Day
        1 Q3W for up to 35 cycles (each cycle length = 21 days).
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Biological: Pembrolizumab'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        pdl1_status: High
        disease_status:
        - Metastatic
        oncotree_primary_diagnosis: Non-Small Cell Lung Cancer
